Boehringer Ingelheim & The Lieber Institute For Brain Development Collaborating On Treatment For Cognitive Deficits Of Neuropsychiatric Disorders

Boehringer Ingelheim and the Lieber Institute for Brain Development (LIBD) announced a joint research and licensing collaboration focused on the development of novel centrally acting COMT (catechol-O-methyltransferase) inhibitors for the potential treatment of cognitive deficits in a spectrum of neuropsychiatric disorders, including schizophrenia. Aligning with a circuitry-based approach to precision psychiatry, the collaboration will leverage Boehringer Ingelheim’s deep experience in central nervous system (CNS) drug discovery and development alongside Lieber’s expertise in centrally acting COMT inhibitors. Ultimately, the partnership will focus on advancing novel COMT inhibitor candidates into the clinic. Financial details of the collaboration . . .